Appendiceal mucinous neoplasm: A Case Report and Literature Review

Chang H et al. Incidental AMN in Hemicolecotomy

Haocheng Chang, Jung-Cheng Kang, Ta-Wei Pu, Ruei-Yu Su, Chao-Yang Chen, Je-Ming Hu

Abstract

BACKGROUND
Appendiceal mucinous neoplasms (AMNs), although not classified as rare, are relatively uncommon tumors most often discovered incidentally during colorectal surgery. Accurate identification of AMNs is difficult due to non-specific symptoms, overlapping tumor markers with other conditions, and the potential for misdiagnosis. This underscores the urgent need for precision in diagnosis to prevent severe complications.

CASE SUMMARY
This case report describes the unexpected discovery and treatment of a low-grade AMN (LAMN) in a 74-year-old man undergoing laparoscopic hemicolecotomy for transverse colon adenocarcinoma. Preoperatively, non-specific gastrointestinal symptoms and elevated tumor markers masked the presence of AMN. The tumor, presumed to be an AMN peritoneal cyst intraoperatively, was confirmed as LAMN through histopathological examination. The neoplasm exhibited mucin accumulation and a distinct immunohistochemical (IHC) profile: positive for CDX2, CK20, SATB2, and MUC2 but negative for CK7 and PAX8. This profile aids in distinguishing appendiceal
and ovarian mucinous tumors. Postoperative recovery was uncomplicated, and the patient initiated adjuvant chemotherapy for the colon adenocarcinoma.

CONCLUSION
This case highlights the diagnostic complexity of AMNs, emphasizing the need for vigilant identification to avert potential complications, such as pseudomyxoma peritonei.

Key Words: adenocarcinoma; appendiceal neoplasms; case report; low-grade appendiceal mucinous neoplasm; peritoneal neoplasms; pseudomyxoma peritonei


Core Tip: In this case, an appendiceal mucinous neoplasm (AMN) was incidentally identified during a laparoscopic hemicolecctomy performed to treat adenocarcinoma in the transverse colon of a 74-year-old male. The presentation underscores the diagnostic complexity posed by AMNs, which often manifest nonspecifically and may be mistaken for other malignancies. The critical role of immunohistochemical analysis in establishing a definitive diagnosis and informing surgical strategy is highlighted, with a particular focus on averting misdiagnosis and potential complications, such as pseudomyxoma peritonei.

INTRODUCTION
Appendiceal mucinous neoplasm (AMN) is an uncommon malignancy originating from the epithelium of the appendix, often incidentally discovered during surgical procedures. Symptoms may be absent or nonspecific, making preoperative identification difficult. In females, elevated tumor markers (CA 19-9, CA 125, or carcinoembryonic antigen) can lead to misdiagnosis, particularly as ovarian cancer [1-3].
As such, AMN should be considered in the differential diagnosis of asymptomatic right adnexal cystic masses, particularly in postmenopausal women with increased tumor marker levels. Surgical removal, prioritizing the prevention of appendiceal rupture to avoid mucin spread and potential pseudomyxoma peritonei (PMP), is the preferred treatment.

Herein, we report the case of a 74-year-old male in whom a low-grade AMN (LAMN), initially misdiagnosed as a peritoneal cyst, was incidentally discovered during laparoscopic extended right hemicolectomy for transverse colon adenocarcinoma. The patient’s preoperative CEA level was elevated at 7.81 ng/mL, and imaging revealed a large cyst in the right lower quadrant of the abdomen. These findings contributed to the initial misdiagnosis of peritoneal cyst, as the possibility of synchronous malignancies was not adequately considered. This case highlights the importance of considering concurrent lesions of different cancers in the differential diagnosis of patients with elevated CEA levels and abdominal cysts, even in the presence of a known malignancy.

**CASE PRESENTATION**

**Chief complaints**

A 74-year-old Chinese man presented the gastrointestinal outpatient clinic with gastrointestinal discomfort and occult blood in the stool.

**History of present illness**

The patient’s condition was characterized by an unexplained weight loss and hematochezia for 6 months. Colonoscopy revealed obstructive adenocarcinoma in the transverse colon, causing further investigative challenges (Figure 1).

**History of past illness**

The patient underwent extended right hemicolectomy during surgery. A 6-cm transverse colon tumor with regional lymph nodes was excised, along with a 9-cm encapsulated appendiceal mass. Histopathological analysis revealed a 4 × 4-cm
ulcerative colon tumor infiltrating the muscularis layer and a diffusely enlarged 6 × 9-cm appendix with a significantly thinned mucin-filled wall with no solid components (Figure 4a-e). Postoperatively, the patient was extubated and transferred to the intensive care unit (ICU), where he showed an unremarkable postoperative course. Flatus occurred on the second postoperative day, and oral intake was initiated on the third day. After stable progress in the ICU, the patient was moved to the surgical ward on postoperative day 5 and discharged on postoperative day 7, with satisfactory nutritional recovery.

*Personal and family history*

The patient denied any family history of malignant tumors.

*Physical examination*

During physical assessment, the patient's vital signs were recorded as follows: body temperature of 36.0 °C, blood pressure of 100/62 mmHg, heart rate of 55 beats per minute, and respiratory rate of 18 breaths per minute. A subsequent routine health examination revealed an ulcerative mass exhibiting irregular mucosal folds and lumen constriction within the transverse colon, which was histopathologically confirmed as adenocarcinoma.

*Laboratory examinations*

Preoperative laboratory evaluations revealed a normal complete blood count, including a white blood cell count of 7,830/μL, red blood cell count of 4,250/μL, mean corpuscular volume of 87.8 fL, mean corpuscular hemoglobin of 27.5 pg, and mean corpuscular hemoglobin concentration of 31.4 g/dL. The coagulation panel revealed an international normalized ratio of 1.0 and an activated partial thromboplastin time of 34.4 s. Overall, the patient's blood work demonstrated no significant abnormalities. Tumor marker analysis revealed normal alpha-fetoprotein levels (2.80 ng/mL), elevated carcinoembryonic antigen (CEA) levels (9.05 ng/mL), and normal CA19-9 Levels (12.2
U/mL). Squamous cell carcinoma antigen (0.5 ng/mL) and prostate-specific antigen (PSA) (0.702 ng/mL) remained within the normal ranges.

**Imaging examinations**
Computed tomography and magnetic resonance imaging confirmed transverse colon wall thickening and regional lymphadenopathy and identified a 9-cm mesenteric cystic mass, supporting the clinical diagnosis of transverse colon adenocarcinoma (Figures 2 and 3).

**FINAL DIAGNOSIS**
Pathological examination of the transverse colon revealed a 35.0-cm segment harboring three ulcerative tumors invading the muscularis propria. Two of these tumors were well-differentiated, while the third showed only moderate differentiation. Metastasis was identified in only one of the 26 examined lymph nodes (pT3N1aMx, mpStage IIIb). IHC analysis confirmed EGFR positivity (1+) and intact expression of MMR proteins, suggesting a low probability of microsatellite instability-high (MSI-H) status.

Examination of the appendiceal lesion revealed a 10.6 x 4.0 x 3.3-cm LAMN filled with mucinous material. The neoplasm was lined by tall columnar epithelial cells exhibiting low-grade dysplastic alterations, embedded within a fibrous stromal matrix. IHC markers confirmed the diagnosis of LAMN (CDX2, CK20, SATB2, and MUC2 positive; CK7 and PAX8 negative). LAMNs confined by the muscularis propria, such as in the present case, are classified as stage TisN0M0 according to the American Joint Committee on Cancer (AJCC) ninth edition.

The patient was finally diagnosed with transverse colon adenocarcinoma, classical subtype, with lymphovascular invasion (mpStage IIIb), and concurrent LAMN, stage TisN0M0.
TREATMENT
In the postoperative phase, the patient exhibited a favorable recovery, culminating in discharge on the seventh day following the surgical procedure. Four weeks after surgery, the patient commenced a chemotherapeutic regimen comprising folinic acid, fluorouracil, and oxaliplatin (FOLFOX).

OUTCOME AND FOLLOW-UP
One month following surgery, the patient's CEA levels presented a slight increase (7.81 ng/mL), albeit with a significant decrease compared to the initial reference point. Concurrent chest and abdominal radiographic evaluations showed no abnormalities, and the surgical wound exhibited satisfactory healing.

DISCUSSION
AMN is a relatively rare pathological condition characterized by the cystic dilation of the appendiceal lumen filled with mucinous content. Clinically, AMNs can present with various syndromes, or may be detected incidentally. Epidemiological data suggest that AMNs occur in approximately 0.2-0.4% of appendectomy specimens and constitute 0.4-1% of all gastrointestinal malignancies in the United States, with an estimated 1,500 new cases each year [1-5].

Individuals with appendiceal tumors may present with non-specific clinical symptoms, leading to potential delays in diagnosis [6, 7]. In the early stages of the disease, symptoms may resemble acute appendicitis, often manifesting as right lower quadrant pain, which can be attributed to mucin-induced distension of the appendix [8]. Complications such as appendicitis or perforation of the appendix can occur if the neoplasm obstructs the appendiceal lumen. A previous study reported that 32% of patients with appendiceal neoplasms are preliminarily diagnosed with acute appendicitis before surgery, and in 23% of cases, the diagnosis is incidental [9].
In the advanced stages of the disease, patients may exhibit increased abdominal girth, often due to the accumulation of mucinous ascitic fluid within the peritoneal cavity. Other clinical features at this stage may include chronic abdominal pain, significant weight loss, anemia, infertility, and the development of umbilical or inguinal hernias. Although mucinous implants are frequently found on peritoneal, serosal, and omental layers, the initial presentation involving intestinal obstruction is uncommon.

Preoperative diagnosis of appendiceal mucoceles poses significant challenges owing to its typically asymptomatic nature and non-specific clinical manifestations. Diagnostic imaging techniques, such as ultrasound and computed tomography (CT), are commonly used to detect these lesions. CT scans are particularly useful, often revealing well-circumscribed, round, cystic lesions with thin walls; in addition, calcifications are observed in approximately 55% of instances. Enhanced nodules within the mucocele wall suggest cystadenocarcinoma. Mucoceles < 2 cm rarely exhibit malignant features, whereas those < 6 cm are frequently associated with cystadenoma or cystadenocarcinoma, carrying a perforation risk of approximately 20%. CT may also show scalloping effects, indicative of malignancy, resulting from mucin-secreting cells adhering to static areas within the gut lumen that are later dislodged by peristalsis. Ultrasound can provide additional insights, sometimes showing a cystic structure adherent to the cecum with an “onion skin” pattern. Colonoscopy offers supplementary diagnostic insights, occasionally identifying a submucosal mass with a yellowish hue over the cecum. Rarely, the “volcano sign” — describing an appendiceal orifice centered within the mass — can be observed. Despite these diagnostic tools, a precise preoperative diagnosis is confirmed in only approximately 30% of the patients. Comprehensive evaluation is imperative for individuals diagnosed with appendiceal mucocele to rule out synchronous neoplastic conditions.
Historically, the taxonomy of appendiceal adenocarcinomas has been debated, yielding disparate conclusions. The PSOGI consensus provides a classification system for appendiceal and peritoneal lesions. Appendiceal mucinous lesions are histologically categorized as non-neoplastic or neoplastic epithelial lesions. The neoplastic forms can be further subdivided into serrated polyps, hyperplastic polyps, LAMNs, high-grade appendiceal mucinous neoplasms, and mucinous adenocarcinomas. An accurate histopathological analysis of the entire appendiceal specimen is critical to ensure an accurate diagnosis. Specifically, the identification of epithelial invasion within the appendiceal wall is pivotal for distinguishing adenocarcinomas from other mucinous lesions. The presence of this key histological indicator can be challenging to ascertain as overt invasion may not be evident and may instead present as fibrotic attenuation of the mural layers, with or without mucin penetration. Current classification systems for these neoplastic lesions take into account the histological appearance of the epithelial layer and the pattern of involvement of the appendiceal wall.

In the realm of appendiceal mucinous neoplasms, the TNM classification system delineated by the AJCC serves as a preliminary framework for staging. This system involves methodical evaluation of the dimensions and invasion depth of the primary tumor, the extent of lymph node involvement, presence of distant metastasis, and histological grade. Distinctions in survival rates are apparent when comparing non-mucinous tumors with mucinous histology.

In a previous study, in the cohort with non-mucinous histologic types, 5-year survival rates were 90.34%, 87.97%, 75.47%, and 59.84% for stages I, IIA, IIB, and IIC, respectively. Notably, patients with stages IIIA and IIB disease exhibited more favorable prognoses, with 5-year survival rates of 82.02% and 64.07%, respectively. Conversely, the prognosis declined precipitously for patients with stage IVA, IVB, and IVC disease, with survival rates of only 34.84%, 23.50%, and 14.18%, respectively.
Despite the in-situ nature of the AMN, the possibility of metastasis must still be considered. In our case, the patient had coexisting transverse colon cancer, specifically the classical adenocarcinoma subtype, which virtually eliminated the possibility of a metastatic origin for the AMN. However, it is important to remember that colon tumors can exhibit a range of subtypes. Currently, four main subtypes are recognized: classical adenocarcinoma (AC), mucinous adenocarcinoma (MAC), signet-ring cell carcinoma (SC), and mixed subtypes[27-29]. Of note, MAC may also develop in the colon, meaning that metastatic concerns should not be excluded. To date, no studies have yet reported a double tumor of MACs due to its rarity.

In contrast to patients with non-mucinous tumors, patients with mucinous and signet ring cell appendiceal cancers demonstrated a more systematic hierarchical order in 5-year overall survival rates when grouped by pathological stage. Specifically, individuals with mucinous histology at stage I had a 5-year survival rate of 92.80%, with a sequential decrease noted across advancing stages: 84.32% for stage II A, 79.71% for stage II B, 72.07% for stage II C, 58.01% for stage III A to III C, 63.25% for stage IVA to IV B, and 46.81% for stage IVC [26]. Moreover, the survival metrics for patients presenting with signet ring cell histology were as follows: 86.67% for stage I, which decreased to 60.82% for stages II A through II C, and markedly lower for stages IVA through IV B at 10.26%, with stage IVC disease showing a survival rate of 12.81% [26].

The management strategy for AMN is contingent upon the initial diagnostic findings, particularly the presence of perforation. A treatment algorithm for appendiceal mucinous neoplasms, as proposed by Govaerts et al [30] and Shaib et al [31], is depicted in Table 2. Appendectomy is generally prescribed for straightforward mucoceles. To rule out mucinous adenocarcinoma, histopathological evaluation of frozen sections of the appendiceal base is recommended [18,30]. In cases of mucinous adenocarcinoma without perforation and mesenteric lymph node involvement or encroachment on surrounding
tissues, a simple appendectomy coupled with mesenteric excision is often deemed adequate \cite{30,31}. In contrast, in instances where diagnostic ambiguity prevails, a more aggressive surgical approach, such as cecal resection, right hemicolecotomy, or cytoreductive surgery, may be recommended \cite{31}. A thorough abdominal assessment is considered crucial for all patients undergoing surgical treatment for AMN \cite{18,30-32}.

Surgical excision of benign mucocele, mucosal hyperplasia, and mucinous adenocarcinoma typically results in excellent outcomes, with 5-year survival rates reported ranging between 90% and 100% \cite{18,26}. The development of recurrent disease following resection, such as pseudomyxoma peritonei or metachronous colonic carcinoma, is a relatively rare event \cite{18}. Likewise, mucinous adenocarcinoma that remain localized in the appendix and have not invaded the base or adjacent organs are associated with highly favorable prognoses. Nevertheless, in cases with peritoneal spread or pseudomyxoma peritonei, the 5-year survival rates are significantly reduced, dropping to approximately 25\% \cite{13}.

Postoperative histopathological assessment of AMN relies heavily on mucin detection. AMNs characteristically exhibit consistent positivity for cytokeratin 20 (CK20) in all cases (100\%), with CK7 negativity in 71\% of cases. Additionally, these neoplasms frequently express MUC5AC (86\%) and DPC4/SMAD4 (100\%). It is worth noting that both colorectal carcinoma (CRC) and appendiceal tumors typically present with a patchy CK7 and a diffuse CK20 staining pattern \cite{33,34}. However, distinguishing primary ovarian mucinous tumors from appendiceal mucinous neoplasms that have metastasized to the ovary presents diagnostic difficulties owing to similarities in the morphological characteristics and IHC profiles of conventional markers. Strickland et al suggested the utility of additional markers, including SATB2, CK20, MUC2, and PAX8, in the differential diagnosis. SATB2 is positive in 93.8\% of appendiceal tumors and is rarely positive in ovarian tumors, demonstrating 97.5\% specificity for the appendiceal origin. CK20, CDX2, and MUC2 are typically strongly and diffusely positive in
appendiceal tumors, whereas ovarian tumors may exhibit positivity, but with a patchy
distribution and less intensity. CK7 expression was observed in 97.5% of ovarian
tumors compared to 31.2% of appendiceal tumors. PAX8 is positive in 70% of ovarian
tumors but is consistently negative in appendiceal tumors. These markers are
recommended as markers for the evaluation of ovarian mucinous tumors, particularly
when clinical or pathological indications suggest a secondary origin.

Our case serves as a pertinent example of the diagnostic intricacies associated with
AMNs and underscores the importance of their consideration in differential diagnoses,
especially when a right adnexal or mesenteric mass is detected via imaging. Initially, the
rarity of AMNs led to the misinterpretation of the cystic fluid observed on CT and MRI
as a simple cyst, inadvertently posing the risk of PMP. Furthermore, the patient's
elevated tumor marker levels and gastrointestinal symptoms could have been
erroneously ascribed to primary adenocarcinoma. Overall, this case highlights the
critical clinical, diagnostic, and therapeutic conundrums posed by AMNs, emphasizing
the need for increased clinical vigilance to prevent misdiagnosis and ensure optimal
treatment strategies, particularly in individuals undergoing colorectal cancer surgery.

The histopathological evaluation of the tumor in the present case demonstrated IHC
positivity for CDX2, CK20, SATB2, and MUC2 and negativity for CK7 and PAX8,
confirming the diagnosis of a LAMN. This immunoprofile is emblematic of neoplasms
emanating from the appendiceal epithelium, providing a critical distinction between
gastrointestinal and ovarian mucinous tumors that exhibit variant marker expression.
As such, this case report details the innovative application of IHC analysis for the
characterization of AMNs. While AMNs are relatively uncommon, accurate diagnosis
and classification is critical for optimal patient management. Further, despite their
clinical significance, the IHC properties of AMNs remain largely underreported in the
literature. This lack of data poses a significant challenge for pathologists seeking
definitive diagnoses and classifications for these neoplasms. Our report presents
valuable confirmatory evidence for the IHC profile of AMN. Through a comprehensive analysis of IHC markers, we were able to definitively diagnose and classify AMN in our patient. This information played a pivotal role in guiding appropriate treatment decisions.

The strategic application of IHC analysis, as demonstrated in this case report, significantly enhances our ability to accurately identify the origin of and to classify neoplasms. This improved accuracy is crucial for optimal patient management, enabling more tailored and effective therapeutic decision-making. For example, given the shared features between AMNs and ovarian mucinous tumors, female patients with AMNs require a more thorough examination due to the high potential for association. For example, in such cases, SATB2 staining can be particularly helpful for diagnosing ovarian metastases of a low-grade appendiceal mucinous neoplasm[36]. Furthermore, this report contributes significantly to the development of a comprehensive database for future research endeavors. By providing confirmatory evidence of the IHC profile of AMNs, this report lays the basis for a deeper understanding of these neoplasms and the refinement of diagnostic and therapeutic approaches. In conclusion, IHC analysis offers a valuable tool for the characterization of AMNs. This case report highlights the innovative use of these techniques and underscores their potential to improve diagnostic accuracy and inform therapeutic decision-making. As we continue to accumulate data and build a comprehensive database, we will further refine our understanding of AMNs and develop more effective management strategies for patients with this rare but important disease.

CONCLUSION

Appendiceal mucinous neoplasms (AMNs), a heterogeneous group of tumors, are rarely diagnosed before elective surgery, while treatment is guided by both stage and histopathology. Early-stage, low-grade tumors typically require surgical excision, while the optimal management of high-grade tumors remains unclear and necessitates further clinical research. Current treatment options for advanced disease include cytoreductive
surgery followed by hyperthermic intraperitoneal chemotherapy, with preoperative chemotherapy potentially playing an adjunctive role. Although IHC examination is widely accepted as important for the pathological diagnosis of LAMN, and several novel markers have been proposed, it is crucial to remember that immunohistochemistry is not entirely specific and should not be solely relied upon for diagnosis. Clinical and imaging findings remain paramount in diagnosis and treatment decisions. Overall, the diverse treatment landscape for AMNs highlights the critical need for a more comprehensive understanding of this disease.
<table>
<thead>
<tr>
<th>Rank</th>
<th>Primary Source</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ovariancancerandus.blogspot.com</td>
<td>46 words — 1%</td>
</tr>
<tr>
<td>2</td>
<td><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a></td>
<td>45 words — 1%</td>
</tr>
<tr>
<td>4</td>
<td>f6publishing.blob.core.windows.net</td>
<td>38 words — 1%</td>
</tr>
<tr>
<td>5</td>
<td>jmedicalcasereports.biomedcentral.com</td>
<td>19 words — 1%</td>
</tr>
<tr>
<td>6</td>
<td>Stanley Tay, Ferenc Szabo, Brian Spain. &quot;Dental Extraction in a Child with Chronic Idiopathic Thrombocytopenia Purpura&quot;, A &amp; A Case Reports, 2013</td>
<td>14 words — &lt; 1%</td>
</tr>
<tr>
<td>7</td>
<td>mesothelioma.x10.mx</td>
<td>14 words — &lt; 1%</td>
</tr>
<tr>
<td>8</td>
<td><a href="http://www.frontiersin.org">www.frontiersin.org</a></td>
<td>14 words — &lt; 1%</td>
</tr>
</tbody>
</table>
Monika Goyal, Angela M. Ellison, Emily Schapiro. "An Unusual Case of Intussusception", Pediatric Emergency Care, 2010
